US healthcare company Baxter International, which develops products to treat haemophilia, kidney disease, and immune disorders, has secured CE mark approval for both its PrisMax system and TherMax blood warmer.
While PrisMax is Baxter’s next-generation technology for continuous renal replacement and organ support therapies, the TherMax blood warmer is a critical component for extracorporeal therapies.
The PrisMax system, which was launched at the 2018 European Society of Intensive Care Medicine (ESICM) congress in Paris last week, is designed to improve the efficiency of therapy delivery, while also improving treatment accuracy in the ICU.
Baxter Acute Therapies business general manager Reaz Rasul said: “Baxter has been a leader in continuous renal replacement therapy (CRRT) technology for more than 20 years. We’ve built on this expertise to bring to market the most advanced technology currently available that directly addresses what clinicians have said they need to better treat patients: simplicity, efficiency and accuracy.
“The PrisMax system is foundational to accomplishing our shared vision to help transform care for critically ill patients and establish best-in-class treatments for a variety of organ support therapies.”
According to the company, the PrisMax system, in combination with special dialyzers, can be used to deliver extracorporeal therapies to remove waste products, excess fluids and inflammatory mediators.
In addition, the system has the ability to help manage patients with acute kidney injury (AKI).
TherMax features a bi-directional connection with the PrisMax system. It automatically adjusts heating to meet the prescribed return blood temperature.
The device comprises advanced patient safety features to help control blood return temperature, detect leaks, and to ensure the correct setup.
Baxter is planning to commercially launch PrisMax and TherMax in more than 19 countries across Europe.
The company noted that the devices will be first made available in hospitals in Denmark, France, Italy and Sweden.